Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Coeptis Therapeutics Hldgs Inc (COEP)

Coeptis Therapeutics Hldgs Inc (COEP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 64,668
  • Shares Outstanding, K 5,340
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,880 K
  • EBIT $ -13 M
  • EBITDA $ -12 M
  • 60-Month Beta -0.50
  • Price/Sales 124.67
  • Price/Cash Flow N/A
  • Price/Book 5.22

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.49 +15.44%
on 02/05/26
15.94 -24.03%
on 02/02/26
-2.27 (-15.79%)
since 01/13/26
3-Month
10.49 +15.44%
on 02/05/26
21.41 -43.44%
on 11/26/25
-2.04 (-14.42%)
since 11/13/25
52-Week
6.26 +93.45%
on 04/25/25
21.41 -43.44%
on 11/26/25
-0.23 (-1.82%)
since 02/13/25

Most Recent Stories

More News
Coeptis Receives Shareholder Approval Towards Z Squared Merger

WEXFORD, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, today announced...

COEP : 12.11 (+2.45%)
Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared

WEXFORD, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP ) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, , announced...

COEP : 12.11 (+2.45%)
Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating

BRISTOL, Tenn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- VanderbiltReport.com , a financial news and content platform, reports that Coeptis Therapeutics (NASDAQ: COEP) is pioneering a dual-track model designed...

COEP : 12.11 (+2.45%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CYBR, UNP, COEP on Behalf of Shareholders

NEW YORK , Aug. 28, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

UNP : 260.68 (-0.42%)
COEP : 12.11 (+2.45%)
CYBR : 408.85 (-0.09%)
Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd

WEXFORD, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, is pleased...

COEP : 12.11 (+2.45%)
Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared

COEP : 12.11 (+2.45%)
Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

COEP : 12.11 (+2.45%)
Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement

COEP : 12.11 (+2.45%)
COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology

COEP : 12.11 (+2.45%)
Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

COEP : 12.11 (+2.45%)

Business Summary

Coeptis Therapeutics Holdings Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals Inc., is a biopharmaceutical company developing innovative cell therapy platforms for cancer. Coeptis Therapeutics Holdings Inc., formerly known as Bull Horn Holdings Corp.,...

See More

Key Turning Points

3rd Resistance Point 13.23
2nd Resistance Point 12.82
1st Resistance Point 12.46
Last Price 12.11
1st Support Level 11.69
2nd Support Level 11.28
3rd Support Level 10.92

See More

52-Week High 21.41
Fibonacci 61.8% 15.62
Fibonacci 50% 13.84
Last Price 12.11
Fibonacci 38.2% 12.05
52-Week Low 6.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar